GlassScriptPhysician profile
Sudhir Shah
NPI 1356742159
$1,395.74
in general payments reported to CMS, 2019-2025
18 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2021: $22.46 · 2022: $250 · 2023: $247 · 2024: $496 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $227.92 | 2022-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $213.69 | 2019-2024 | Lifevest |
| Pfizer INC. | $204.29 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $132.17 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $108.36 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.71 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $63.54 | 2023-2024 | Ozempic, Rybelsus |
| Inari Medical, INC. | $55.46 | 2022 | |
| Abiomed | $52.34 | 2023-2024 | Impella |
| Lexicon Pharmaceuticals, INC. | $49.65 | 2024 | Inpefa |
| Scpharmaceuticals INC. | $47.79 | 2025 | |
| Abbvie INC. | $28.52 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $27.17 | 2024 | Opsumit |
| E.R. Squibb & Sons, L.L.C. | $23.94 | 2025 | Eliquis |
| Baxter Healthcare | $21.35 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $20.29 | 2023 | Xarelto |
| Biomerieux INC | $19.82 | 2023 | Biofire Blood Culture Identification 2 (Bcid2) Panel |
| Glaxosmithkline, LLC. | $16.73 | 2025 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhir Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.